PL2576582T3 - Leczenie dystrofii mięśniowej - Google Patents

Leczenie dystrofii mięśniowej

Info

Publication number
PL2576582T3
PL2576582T3 PL11787414T PL11787414T PL2576582T3 PL 2576582 T3 PL2576582 T3 PL 2576582T3 PL 11787414 T PL11787414 T PL 11787414T PL 11787414 T PL11787414 T PL 11787414T PL 2576582 T3 PL2576582 T3 PL 2576582T3
Authority
PL
Poland
Prior art keywords
treatment
muscular dystrophy
dystrophy
muscular
Prior art date
Application number
PL11787414T
Other languages
English (en)
Inventor
Joseph Belanoff
Original Assignee
Corcept Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics, Inc. filed Critical Corcept Therapeutics, Inc.
Publication of PL2576582T3 publication Critical patent/PL2576582T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PL11787414T 2010-05-26 2011-05-26 Leczenie dystrofii mięśniowej PL2576582T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34855310P 2010-05-26 2010-05-26
EP11787414.9A EP2576582B1 (en) 2010-05-26 2011-05-26 Treatment of muscular dystrophy
PCT/US2011/038138 WO2011150209A1 (en) 2010-05-26 2011-05-26 Treatment of muscular dystrophy

Publications (1)

Publication Number Publication Date
PL2576582T3 true PL2576582T3 (pl) 2020-06-29

Family

ID=45004382

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11787414T PL2576582T3 (pl) 2010-05-26 2011-05-26 Leczenie dystrofii mięśniowej

Country Status (5)

Country Link
US (1) US11103514B2 (pl)
EP (1) EP2576582B1 (pl)
ES (1) ES2762243T3 (pl)
PL (1) PL2576582T3 (pl)
WO (1) WO2011150209A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
CN110099688A (zh) * 2016-11-17 2019-08-06 赛途公司 骨骼肌肥大诱导物
WO2023086854A1 (en) 2021-11-10 2023-05-19 University Of Rochester Treatment of myotonic disorders
WO2024054793A1 (en) 2022-09-09 2024-03-14 University Of Rochester Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296206A (en) 1980-04-30 1981-10-20 United States Of America Irreversible anti-glucocorticoids
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
US4978657A (en) 1981-01-09 1990-12-18 Roussel Uclaf Novel 11β-substituted-19-nor-steroids
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2639045B2 (fr) 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
DE3438994A1 (de) 1984-10-22 1986-04-24 Schering AG, Berlin und Bergkamen, 1000 Berlin Antigestagene, glukokortikoide und prostaglandine zur geburtseinleitung oder fuer den schwangerschaftsabbruch
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
NZ214998A (en) 1985-02-07 1989-06-28 Schering Ag 13-(methyl or ethyl)-11-beta-phenyl-gonane derivatives; preparatory processes and pharmaceutical compositions
DE3506785A1 (de) 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
US5380840A (en) 1985-09-12 1995-01-10 The Upjohn Company Triazinylpiperazinyl steroids
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
EP0254341B1 (en) 1986-07-23 1990-01-03 Akzo N.V. Novel 18-phenyloestrane derivatives
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US4861763A (en) 1986-09-17 1989-08-29 Research Triangle Institute 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
US4921638A (en) 1986-11-05 1990-05-01 The Upjohn Company 17β-cyano-9α,17α-dihydroxyandrost-4-en-3-one
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3723788A1 (de) 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2618783B1 (fr) 1987-07-30 1991-02-01 Roussel Uclaf Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
JP2785023B2 (ja) 1987-12-30 1998-08-13 ルセル―ユクラフ １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
DE3820948A1 (de) 1988-06-16 1989-12-21 Schering Ag 10ss, 11ss-ueberbrueckte steroide
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5348729A (en) 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
DD289541A5 (de) 1989-08-04 1991-05-02 ��@�K@�������������@�K@��������������@��������k�� Verfahren zur herstellung von 11beta-aryl-16 alpha, 17 alph-cyclohexanoestra-4,9-dienen
US5276023A (en) 1989-08-08 1994-01-04 Roussel Uclaf 19-nor-steroid esters
FR2651233B1 (fr) 1989-08-23 1991-12-13 Roussel Uclaf Nouveaux acides omega-phenylamino alcanouiques substitues sur le noyau aromatique par un radical derive de 19-norsterouides, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant.
US5173405A (en) 1990-01-23 1992-12-22 The United States Of America As Represented By The Department Of Health And Human Services Use of arsenite to reversibly block steroid binding to glucocorticoid receptors in the presence of other steroid receptors
US5616458A (en) 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
DE4042004A1 (de) 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5693646A (en) 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
AU5729098A (en) 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
EP0903146A1 (en) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
PT1023074E (pt) * 1997-10-06 2006-12-29 Trustees Leland Stanford Junio Métodos para tratamento de psicose associada a disfunção relacionada com glucocorticóides
US6960570B2 (en) * 1998-03-18 2005-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU756818B2 (en) * 1998-05-15 2003-01-23 Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid receptor antagonists for the treatment of dementia
WO2000043017A1 (en) * 1999-01-21 2000-07-27 Steroidogenesis Inhibitors International Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
DK1370268T3 (da) * 2001-03-23 2009-09-14 Corcept Therapeutics Inc Fremgangsmåde til behandling af stresssygdomme under anvendelse af glucocorticoid-receptor-specifikke antagonister
AU2002318370A1 (en) * 2001-06-19 2003-01-02 Mouse Specifics, Inc. Method of early detection of duchenne muscular dystrophy and other neuromuscular disease
CA2459033C (en) * 2001-08-31 2012-05-22 Corcept Therapeutics, Inc. Methods for inhibiting cognitive deterioration in adults with down's syndrome
US6622641B2 (en) 2001-10-03 2003-09-23 Rehrig Pacific Company Pallet
FR2850022B1 (fr) * 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
EP1618881A1 (en) * 2004-07-20 2006-01-25 Santhera Pharmaceuticals (Schweiz) GmbH Use of non-glucocorticoid steroids for the treatment of muscular dystrophy
WO2007024535A2 (en) * 2005-08-19 2007-03-01 Wyeth Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
WO2008067480A2 (en) * 2006-11-29 2008-06-05 Nationwide Children's Hospital Myostatin inhibition for enhancing muscle and/or improving muscle function
US8598149B2 (en) * 2007-08-30 2013-12-03 Corcept Therapeutics, Inc. Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists
AU2009267016B2 (en) 2008-07-01 2014-07-03 Corcept Therapeutics, Inc. Use of mifepristone for the treatment of Amyotrophic Lateral Sclerosis

Also Published As

Publication number Publication date
US20110294771A1 (en) 2011-12-01
US11103514B2 (en) 2021-08-31
EP2576582A4 (en) 2013-08-21
WO2011150209A1 (en) 2011-12-01
EP2576582A1 (en) 2013-04-10
EP2576582B1 (en) 2019-09-18
ES2762243T3 (es) 2020-05-22

Similar Documents

Publication Publication Date Title
ZA201304280B (en) Treatment of jak2-mediated conditions
HK1209456A1 (en) Oligonucleotide for the treatment of muscular dystrophy patients
IL220876A0 (en) Treatment of cardiac conditions
PL2652193T3 (pl) Obróbka
EP2611496A4 (en) Methods of Treatment
EP2892525A4 (en) METHODS OF TREATING MUSCLE DYSTROPHY
ZA201301601B (en) Treatment of diseases
SG10201508495VA (en) Combination treatment of cancer
EP2613786A4 (en) TREATMENT OF DISEASES
GB201018147D0 (en) Method of treatment
ZA201207973B (en) Treatment of gout
IL256026B (en) Treatment methods
IL223289A0 (en) Treatment of type 2 diabetes
GB201003920D0 (en) Method of treatment
IL225896A0 (en) Treatment of mecp-2 related disorders
EP2522360A4 (en) VACCINE FOR TAUTOPATHY TREATMENT
PL2576582T3 (pl) Leczenie dystrofii mięśniowej
GB201013573D0 (en) Treatment
ZA201207496B (en) Treatment of chicory
ZA201207497B (en) Treatment of chicory
EP2585103A4 (en) METHOD OF TREATMENT
GB201018149D0 (en) Method of treatment
GB201020015D0 (en) Method of treatment
EP2641609A4 (en) THERAPEUTIC AGENT FOR MUSCLE DYSTROPHY
GB201014097D0 (en) Treatment